The device is a "Miniaturized Ventricular Assist Device" (MVAD). A working group led by Heinrich Schima at the Center for Medical Physics and Biomedical Engineering in Vienna played a major role in the product development process. “We consider this miniaturized pump to be further exceptional progress in heart replacement therapy, which could potentially change therapy for advanced cardiac insufficiency“, says Günther Laufer, Head of the Department of Clinical Heart Surgery. The device, which is a further development in this field, originated at HeartWare International. The pump was implanted at the start of a clinical study to acquire the CE mark required for future routine applications. The first two patients come from Vienna and Newcastle upon Tyne (Freeman Hospital).
The MVAD device is a heart pump which can be programmed to several blood flow profiles in order to support the circulation of patients with advanced cardiac insufficiency. It involves a rotation pump with low shear stress for the red blood corpuscles. The shear stress arising in the rotation pumps present a problem with such pumps. There are four different pulse adjustments in order to optimize the function of the aorta valve and reduce chronic bleeding events.